SSi Mantra Procedures Jump 79% to 14,103 as Global Expansion Accelerates
SSII is trading near its 52-week low of $3.11 (7.7% above the low) on light trading volume (0.3× avg).
Summary
SS Innovations reported cumulative SSi Mantra procedures reached 14,103 as of September 8, a 79% increase from 7,885 at the end of 2025. Installed systems grew to 238, up 42% from 168, with recent launches in Colombia and Sri Lanka expanding the footprint to 12 countries. The company also highlighted 188 robotic telesurgeries and a pediatric kidney procedure on a 45-day-old infant. Regulatory milestones are on the horizon: FDA 510(k) review expected by end of Q1 2027 and EU CE marking potentially by end of 2026. This operational update follows the Q2 revenue beat and the CFO departure in August, showing continued commercial momentum despite governance concerns.
At the time of this announcement, SSII was trading at $3.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $671.6M. The 52-week trading range was $3.11 to $10.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: FinanceWire.